China National Pharmaceutical Foreign Trade To Build Investment Platform For Pharmaceutical Industry

China National Pharmaceutical Foreign Trade Corporation, the wholly owned subsidiary of China National Pharmaceutical Group, has mapped out its medium- and long-term strategy that seeks strategic partnerships to establish an investment platform for the pharmaceutical industry. This will dovetail with the parent group's aim of consolidation and globalization of its pharmaceutical trade, technology and business. The trade corporation has collaborated with Otsuka Group, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, AstraZeneca and Kanebo and set up more than 10 joint ventures such as China Otsuka, Xian-Janssen, Shanghai Squibb, Suzhou Capsugel and Sino-Swed Pharmaceutical. It reported revenue of RMB 2 billion last year, with import and export amounting to RMB $300 million. (Click here for more - Chinese Language)